Dual orexin receptor antagonists, such as suvorexant, have shown promise in reducing amyloid‐β and tau accumulation in Alzheimer's disease, as well as ameliorating sleep alterations in Huntington's and ALS models. The gene discussed is MAPT; the disease is Alzheimer disease.